Showing 1,095 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Opioid Substitutes Do Not Impede Hep C Combo Drugs

Editor's pick
Medscape
18 March 2016
Drug interactions & pharmacokinetics

Sofosbuvir/velpatasvir for hepatitis C can be administered with most antiretrovirals

News
14 March 2016
Hepatitis C treatment

US: VA expands hepatitis C treatment to all patients with the virus

Editor's pick
Military Times
11 March 2016
Pharmaceutical industry

Inside the $100 million ad blitz for a $1100-a-pill drug for hepatitis C

Editor's pick
STAT
9 March 2016
Hepatitis C treatment

Hepatitis medicines: Warning concerning Harvoni® packs with counterfeit contents

Editor's pick
Swiss Agency for Therapeutic Products
8 March 2016
Hepatitis C treatment

20,000 Georgians to Receive Free Hepatitis C Treatment

Editor's pick
Georgia Today
8 March 2016
Pharmaceutical industry

Gilead Spars With Merck Over Hepatitis C $1000-Pill Royalties

Editor's pick
Bloomberg
8 March 2016
New & experimental hepatitis C treatment

Ravidasvir plus sofosbuvir demonstrates high cure rate for people with hepatitis C genotype 4

News
8 March 2016
Hepatitis C treatment

New York Said to Probe Insurers Over Hepatitis C Drugs

Editor's pick
Bloomberg
4 March 2016
Access to healthcare

His Job Is to Sell a $1,000 Pill for $10 Without Losing Money

Editor's pick
Bloomberg
29 February 2016
Hepatitis C treatment

Sofosbuvir/ledipasvir for 6 weeks cures HCV in HIV-positive people with acute HCV if viral load is low

News
26 February 2016
Hepatitis C treatment

New recommendations in the updated WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection

Editor's pick
World Health Organization
25 February 2016
People who inject drugs

Should we focus hepatitis C treatment on some injectors and not others?

Editor's pick
Drug & Alcohol Findings
22 February 2016
Hepatitis C symptoms & diagnosis

Direct-acting antivirals reduce cryoglobulinemia in hepatitis C

News
19 February 2016
Pharmaceutical industry

The cost of curing Hepatitis C

Editor's pick
BBC Newsnight / You Tube
18 February 2016
Hepatitis C treatment

Hepatitis C virus relapse uncommon after sustained virological response

Editor's pick
Medscape
17 February 2016
Hepatitis C treatment

U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease

Editor's pick
Gilead press release
17 February 2016
Hepatitis C treatment

12 Feb 2016: My day of reckoning

Editor's pick
Hep Magazine
12 February 2016
Access to healthcare

Are States Obligated To Provide Expensive Hepatitis C Drugs?

Editor's pick
Kaiser Health News
10 February 2016
Hepatitis C treatment

New cases of hepatitis C in NYC are on the rise

Editor's pick
Politico
9 February 2016
Hepatitis C treatment

mapCrowd: an online data collection platform for hepatitis C information

Editor's pick
Treatment Action Group
9 February 2016
Hepatitis C treatment

Olysio/Sovaldi yield high SVR post-liver transplant

Editor's pick
Healio
8 February 2016
New & experimental hepatitis C treatment

Fair Pricing Coalition Recognizes Merck’s Lower Price for Curative Hepatitis C Treatment, Calls for Manufacturers to Reduce Excessive Prices and Increase Patient Assistance

Editor's pick
Fair Pricing Coalition
8 February 2016
New & experimental hepatitis C treatment

U.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C

Editor's pick
Bristol-Myers Squibb press release
8 February 2016